Madhav Thambisetty

This paper uses network pharmacology to identify and validate drug repurposing candidates for Alzheimer's Disease, finding arundine and TUDCA as promising candidates.

This study links psychosocial experiences to mitochondrial biology in the human brain, finding positive experiences correlate with higher OxPhos machinery abundance and negative experiences with lower abundance.

This study identifies 114 proteins and 5 modules linked to cerebral atherosclerosis in the brain, with 23 proteins and 2 modules also associated with Alzheimer’s dementia, highlighting shared mechanisms involving synaptic signaling and myelination.

The paper identifies protein network modules in Alzheimer's disease brains and cerebrospinal fluid that are associated with energy metabolism and neuroinflammation, suggesting potential biomarkers and therapeutic targets.

The paper identifies 579 proteins associated with cognitive trajectory in aging using proteomic analysis of human prefrontal cortex, highlighting mitochondrial and synaptic processes linked to cognitive stability.

The paper investigates neurotransmitter imbalances in Alzheimer's disease by analyzing metabolite levels in brain regions of control, AD, and asymptomatic AD groups.

This paper reports the first human PET study of three novel tau radiopharmaceuticals, finding that [18F]RO-948 shows superior characteristics for tau pathology characterization in Alzheimer's disease.